- Details
- Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...
|
- Details
- Guru Sonpavde joins Alicia Morgans, MD, MPH in a discussion on the treatment landscape of muscle-invasive bladder cancer and several trials that could lead to changes in treatment patterns across the bladder cancer disease spectrum. They review data recently presented at the 2020 European Society for Medical Oncology Virtual Congress, (ESMO) including sacituzumab govitecan in Cohort 3 of the TROPH...
|
- Details
- The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH highlighting promising data from a different antibody-drug conjugate called sacituzumab govitecan (IMMU-132). There are a number of ongoing studies where sacituzumab govitecan which is being studied in advanced bladder cancer. Enfortumab vedotin targets Nectin-4, while sacituzumab govitecan is targeting Trop-2. Dr. Grivas highlights the final r...
|
- Details
- In this clinical conversation with Alicia Morgans, MD, MPH, and Joshua Meeks, MD, PhD we hear their clinical perspective combination therapies when treating metastatic urothelial carcinoma. They discuss several studies with recent data from the European Society for Medical Oncology Virtual Congress, (ESMO) 2020 including the KEYNOTE-361 the DANUBE trial, and the IMvigor130 data presented at earlie...
|
- Details
- Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...
|
- Details
- Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...
|
- Details
- Makarand Khochikar, President of the Urological society of India –West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj, joins Ashish Kamat, MD to discuss the case of a 70-year-old patient who presented with left-side loin pain and intermittent hematuria. An ultrasound and CT scan revealed a solid-lesion in the left kidney, lesions in the left...
|
- Details
- Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...
|